Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)

Status unconfirmed · Phase 2

Conditions studied: Myelodysplastic Syndrome

In brief

The purpose of this study is to determine the safety and efficacy of DN-101 (calcitriol) in patients with myelodysplastic syndrome who are dependent on repeat blood transfusions.

Key facts

Study ID

NCT00057031

Run by

Novacea

People needed

46

Starts

2002-11-01

Expected to finish

2004-03-01

Last updated by the study team

2006-11-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Clinical Research Consultants, Inc. — Hoover, Alabama, United States
• University of California, San Francisco — San Francisco, California, United States
• James A. Haley Veterans Hospital — Tampa, Florida, United States
• Rush Cancer Institute MDS Center — Chicago, Illinois, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• The Cleveland Clinic Foundation, Taussig Cancer Center — Cleveland, Ohio, United States
• Oregon Health Sciences University — Portland, Oregon, United States
• Boston Baskin Cancer Group — Memphis, Tennessee, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.